Year archive

Compugen Ltd. — 2024 filings

All 65 regulatory filings released by Compugen Ltd. (CGEN) in 2024, sourced directly from the official regulator.

65 Filings

2024 Period

2024 filings (65)

Filing	Released	Lang
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies Regulatory Filings	2024-11-27	English
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies Report Publication Announcement	2024-11-27	English
Compugen Reports Third Quarter 2023 Results Interim / Quarterly Report Q3 2024	2024-11-12	English
Compugen Reports Third Quarter 2023 Results Report Publication Announcement	2024-11-12	English
Compugen to Participate in Stifel 2024 Healthcare Conference Investor Presentation	2024-11-11	English
Compugen to Participate in Stifel 2024 Healthcare Conference Report Publication Announcement	2024-11-11	English
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 Regulatory Filings	2024-11-05	English
Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 Report Publication Announcement	2024-11-05	English
to Release Third Quarter 2024 Financial Results and conference call on Tuesday, November 12, 2024 Earnings Release Q3 2024	2024-10-29	English
to Release Third Quarter 2024 Financial Results and conference call on Tuesday, November 12, 2024 Report Publication Announcement	2024-10-29	English
To Present New Clinical Data at SITC 2024 Investor Presentation	2024-10-07	English
To Present New Clinical Data at SITC 2024 Report Publication Announcement	2024-10-07	English
Results of an Annual Meeting of Shareholders held on September 12, 2024 Regulatory Filings	2024-09-13	English
Results of an Annual Meeting of Shareholders held on September 12, 2024 Report Publication Announcement	2024-09-13	English
to Present at Single Cell Genomics 2024 Conference Regulatory Filings	2024-09-09	English
to Present at Single Cell Genomics 2024 Conference Report Publication Announcement	2024-09-09	English
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference Report Publication Announcement	2024-08-29	English
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference Report Publication Announcement	2024-08-29	English
Immediate Report about change of identifying details Regulatory Filings	2024-08-27	English
Second Quarter 2024 Results Interim / Quarterly Report Q2 2024	2024-08-06	English
Second Quarter 2024 Results Report Publication Announcement	2024-08-06	English
annual general meeting of shareholders to be held on September 12, 2024 AGM Information	2024-08-05	English
annual general meeting of shareholders to be held on September 12, 2024 AGM Information	2024-08-05	English
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors Regulatory Filings	2024-07-29	English
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors Report Publication Announcement	2024-07-29	English
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024, conference call and webcast at 8:30 AM ET Report Publication Announcement	2024-07-23	English
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024, conference call and webcast at 8:30 AM ET Report Publication Announcement	2024-07-23	English
Compugen to Present at Upcoming Antibody Industrial Symposium Investor Presentation	2024-06-17	English
Compugen to Present at Upcoming Antibody Industrial Symposium Report Publication Announcement	2024-06-17	English
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig Regulatory Filings	2024-05-30	English
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig Report Publication Announcement	2024-05-30	English
Reports First Quarter 2024 Results Earnings Release Q1 2024	2024-05-20	English
Reports First Quarter 2024 Results Report Publication Announcement	2024-05-20	English
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential Regulatory Filings	2024-05-16	English
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential Report Publication Announcement	2024-05-16	English
Compugen Appoints David Silberman as Chief Financial Officer Board/Management Information	2024-05-15	English
Compugen Appoints David Silberman as Chief Financial Officer Report Publication Announcement	2024-05-15	English
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024, conference call and webcast to review the results and provide a corporate update at 8:30 AM ET Report Publication Announcement	2024-05-06	English
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024, conference call and webcast to review the results and provide a corporate update at 8:30 AM ET Report Publication Announcement	2024-05-06	English
to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 Regulatory Filings	2024-04-25	English
to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 Report Publication Announcement	2024-04-25	English
Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 Regulatory Filings	2024-04-10	English
Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 Report Publication Announcement	2024-04-10	English
Compugen to Participate in Two Upcoming Investor Conferences Investor Presentation	2024-04-03	English
Compugen to Participate in Two Upcoming Investor Conferences Report Publication Announcement	2024-04-03	English
Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy Report Publication Announcement	2024-03-11	English
Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy Report Publication Announcement	2024-03-11	English
to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 Regulatory Filings	2024-03-06	English
to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 Report Publication Announcement	2024-03-06	English
FORM 20-F For the fiscal year ended December 31, 2023 Annual Report FY 2023	2024-03-06	English
FORM 20-F For the fiscal year ended December 31, 2023 Report Publication Announcement	2024-03-06	English
Form 6-K- Fourth quarter and full year 2023 results Earnings Release Q4 2023	2024-03-05	English
Form 6-K- Fourth quarter and full year 2023 results Report Publication Announcement	2024-03-05	English
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 Regulatory Filings	2024-02-26	English
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024 Report Publication Announcement	2024-02-26	English
to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024, conference call at 8:30 AM ET Report Publication Announcement	2024-02-20	English
to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024, conference call at 8:30 AM ET Report Publication Announcement	2024-02-20	English
Appointment of Michelle Mahler M.D. as Chief Medical Officer Board/Management Information	2024-02-15	English
Appointment of Michelle Mahler M.D. as Chief Medical Officer Report Publication Announcement	2024-02-15	English
Form 6-K-Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement;Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Regulatory Filings	2024-01-08	English
Form 6-K-Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement;Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Report Publication Announcement	2024-01-08	English
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer Regulatory Filings	2024-01-08	English
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer Report Publication Announcement	2024-01-08	English
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement Regulatory Filings	2024-01-08	English
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement Report Publication Announcement	2024-01-08	English

Filings by year

2026 60 filings
2025 58 filings
2024 65 filings
2023 94 filings
2022 84 filings
2021 66 filings
2020 58 filings
2019 22 filings
2018 53 filings
2017 33 filings
2016 29 filings
2015 44 filings
2014 68 filings
2013 40 filings
2012 33 filings
2011 51 filings
2010 42 filings
2009 65 filings
2008 56 filings
2007 48 filings
2006 28 filings
2005 28 filings
2004 34 filings